Allow us to explain that headline.
Food Science & Nutrition has retracted a 2018 article by a group of researchers in China and Pakistan for plagiarism. The article was titled “Experimentally investigated the asparagus (Asparagus officinalis L.) drying with flat-plate collector under the natural convection indirect solar dryer.”
Per the retraction notice: Continue reading When is asparagus not asparagus? Why, when it’s ginger, of course!
In July 2017, a JAMA journal called for an investigation into a 2013 paper it had published after concluding that the article had “scientific and ethical concerns.” Now the journal, JAMA Otolaryngology − Head & Neck Surgery, is retracting the paper.
The article, “Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial,” came from a group in Italy led by Mario Schietroma, of the Department of Surgery at the University of L’Aquila, in Abruzzo, Italy. Schietroma, who in December admitted to us that a retracted 2015 paper of his in the Journal of the American College of Surgeons suffered from “misinterpretation of the statistical data,” now has four retractions.
The paper has been cited a total of 18 times, according to Clarivate Analytics’ Web of Science, including twice since it was subjected to an expression of concern. One of those citations was by a Cochrane systematic review.
According to the retraction notice: Continue reading JAMA journal retracts paper when author can’t produce original data
The FDA has walked away from a 2010 rule that would have forced drug makers to disclose fabricated data to regulators.
As Bloomberg Law reported last week, the FDA has withdrawn the proposed rule, “Reporting Information Regarding Falsification of Data,” which would Continue reading As China cracks down on faked drug trial data, US FDA abandons disclosure rule
On Friday we reported on the case of a group of researchers in China who have retracted at least 11 papers for various kinds of misconduct. Here’s a bit more on that story, courtesy of our commenters.
First, it turns out that the retraction total is at least 12. But more significant is that the institution in question, Tsinghua University’s Graduate School at Shenzhen, announced yesterday that it had stripped one of the researchers involved in the studies of his PhD and sanctioned another in the matter. Continue reading Graduate student in China stripped of PhD after investigation that led to a dozen retractions
A group of materials scientists in China has earned 11 retractions and three corrections — so far — for image manipulation, duplication, deceptive authorship and other misconduct.
The papers, from a group at the prestigious Tsinghua University, appeared in a variety of materials journals and date back to 2014. The most recent publications arrived in 2016.
[Please see an update on this post.]
The notices read pretty much the same way. Here, for example, is the retraction statement for “Effects of high-energy electro-pulsing treatment on microstructure, mechanical properties and corrosion behavior of Ti–6Al–4V alloy,” which was published in 2015 in Materials Science and Engineering C, an Elsevier title: Continue reading Group in China earns nearly a dozen retractions for image duplication, forged authorship, and more
The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.
According to the notice: Continue reading “Sufficiently serious” issues in study prompt company to yank drug approval application in China
A surgeon in Scotland who mistook a tear duct for a brain tumor, operated on the wrong disc in another patient and eventually gave up his right to practice medicine in the UK has corrected a 2008 paper.
The reason: More confusion, it seems. Muftah Salem Eljamel says he mistook an image in the article as being from his hospital when it belonged to another surgeon at a hospital in Cardiff, some 460 miles distant. And oh, the image wasn’t what he thought it was to begin with. The Courier reported on the correction.
According to the notice, in the Journal of Neurosurgery: Continue reading Dr. What? From the mixed-up files of Muftah Salem Eljamel
Here’s a head-scratcher from the Journal of Affective Disorders, which has retracted a 2017 article for, well, reasons we invite you to divine.
The article, “The effectiveness of group-based behavioral activation in the treatment of depression: An updated meta-analysis of randomized controlled trial,” was published by a group at the Jockey Club School of Public Health and Primary Care, part of the the Chinese University of Hong Kong.
According to the retraction notice: Continue reading A paper from the Jockey Club School makes a false start
A toxicology journal has issued an expression of concern for a group of papers about the controversial herbicide glyphosate after concluding that some of the authors didn’t adequately disclose their ties to the maker of the product.
At issue are five articles that appeared in a 2016 supplement to Critical Reviews in Toxicology, a Taylor & Francis title, about the chemical, the active ingredient in Monsanto’s blockbuster weed-killer Roundup. Although the authors of the articles don’t overlap perfectly, Keith Solomon, of the University of Guelph, in Canada, appears on three of the articles; Gary Williams, of New York Medical College, appears on three as well.
Williams was caught up in a ghost-writing scandal after court documents revealed that he had put his name on a published paper written by Monsanto employees. Solomon served on a panel funded by Monsanto that undercut the conclusions of a report from the World Health Organization that glyphosate is probably cancerous to people.
According to the expression of concern, which was first reported by Bloomberg today: Continue reading Journal flags papers, saying authors didn’t adequately disclose ties to Monsanto
Researchers in China have retracted a pair of papers in the same journal after running into “irreconcilable” differences with the articles.
Both articles appeared in Molecular Medicine Reports, from Spandidos.
One article, “Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal stem cell transplantation improves bone repair in a rabbit model of bone nonunion,” published in November 2017, suffered from, well, serious nonunion: Continue reading “Irreconcilable” differences about author order, other issues topple two articles in Spandidos journal